melarsoprol has been researched along with arsenic trioxide in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gabrilove, JL; Jakubowski, A; König, A; Pandolfi, PP; Rivi, R; Warrell, RP; Wrazel, L | 1 |
| Delva, L; Gabrilove, JL; Gambacorti-Passerini, C; König, A; Pandolfi, PP; Rivi, R; Scheinberg, DA; Wang, ZG; Warrell, RP | 1 |
| Brouet, JC; Fermand, JP; Labaume, S; Larghero, J; Marolleau, JP; Noguera, MH; Rousselot, P | 1 |
| Warrell, RP | 1 |
| Brouet, JC; Chopin, M; Dosquet, C; Fermand, JP; Janin, A; Labaume, S; Larghero, J; Marolleau, JP; Poupon, J; Rousselot, P | 1 |
| Ajana, I; Astier, A; Gibaud, S | 1 |
| Aniceto, N; Astier, A; Becherirat, S; Gibaud, S; Lanhers, MC; Loboda, C; Socha, M; Yemloul, M | 1 |
1 review(s) available for melarsoprol and arsenic trioxide
| Article | Year |
|---|---|
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin | 1999 |
6 other study(ies) available for melarsoprol and arsenic trioxide
| Article | Year |
|---|---|
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Transformed; Cell Survival; DNA Damage; DNA Fragmentation; Drug Screening Assays, Antitumor; Herpesvirus 4, Human; Humans; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Melarsoprol; Oxides; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Division; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Melarsoprol; Mice; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1998 |
Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line; Cell Survival; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Humans; Kinetics; Lymphocyte Activation; Melarsoprol; Multiple Myeloma; Neoplasm Proteins; Nuclear Proteins; Oxides; Plasma Cells; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 1999 |
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Division; Humans; Immunoglobulin G; Melarsoprol; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms, Experimental; Oxides; Plasma Cells; Receptors, Interleukin-6; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays | 2004 |
Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Brain; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Melarsoprol; Mice; Mice, Inbred Strains; Nanotechnology; Oxides; Suspensions | 2009 |
The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Cyclodextrins; Brain Neoplasms; Cell Line, Tumor; Excipients; Female; Glioma; Humans; Injections, Intraperitoneal; Magnetic Resonance Spectroscopy; Melarsoprol; Mice; Mice, Nude; Oxides; Xenograft Model Antitumor Assays | 2013 |